Table 1.
Patient characteristics.
| Before PS matching | After PS matching | ||||||
|---|---|---|---|---|---|---|---|
| TA-TMA | non-TA-TMA | P-value | TA-TMA | non-TA-TMA* | P-value | ||
| n | 16 | 93 | 15 | 15 | |||
| Median age [range] | 54.5 [36–68] | 46 [19–68] | 0.005 | 55 [36–68] | 58 [40–67] | 0.59 | |
| Sex | male/female | 8/8 | 54/39 | 0.59 | 8/7 | 8/7 | 1 |
| Disease (%) | 0.06 | 0.73 | |||||
| AML | 3 (19) | 39 (42) | 3 (20) | 5 (33) | |||
| ALL | 2 (13) | 23 (25) | 2 (13) | 2 (13) | |||
| MDS | 4 (25) | 11 (12) | 3 (20) | 2 (13) | |||
| other | 7 (44) | 20 (22) | 7 (46) | 6 (40) | |||
| Disease status | CR/non-CR | 5/11 | 53/40 | 0.06 | 5/10 | 4/11 | 1 |
| HLA disparity | match/mismatch/unknown | 6/10/0 | 41/51/1 | 0.82 | 5/10/0 | 4/11/0 | 1 |
| Conditioning intensity | MAC/RIC | 3/13 | 48/45 | 0.016 | 3/12 | 4/11 | 1 |
| Graft source (%) | 0.94 | 0.41 | |||||
| BM | 5 (31) | 28 (30) | 4 (27) | 4 (27) | |||
| PB | 9 (56) | 48 (52) | 9 (60) | 6 (40) | |||
| CB | 2 (13) | 17 (18) | 2 (13) | 5 (33) | |||
| GVHD prophylaxis | CsA/Tac based | 2/14 | 34/59 | 0.083 | 2/13 | 1/14 | 1 |
| CMV sero-status in recipient | positive/negative | 15/1 | 76/17 | 0.46 | 14/1 | 12/3 | 0.6 |
*including one duplicated patient.
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BM, bone marrow; CB, cord blood; CMV, cytomegalovirus; CR, complete response; CsA, cyclosporine; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; PB, peripheral blood; PS, propensity score; RIC, reduced intensity conditioning; Tac, tacrolimus; TA-TMA, transplant-associated thrombotic microangiopathy.